Bacteremia and Blood Culture Utilization During COVID-19 Surge in New York City

- 3 Jorge Sepulveda, MD, PhD¹, Lars F. Westblade, PhD^{2,3}, Susan Whittier, PhD¹, Michael J. Satlin, MD³,
- 4 William G. Greendyke, MD⁴, Justin G. Aaron, MD⁴, Jason Zucker, MD⁴, Donald Dietz, MD⁴, Magdalena
- Sobieszczyk, MD⁴, Justin J. Choi, MD³, Dakai Liu, PhD⁵, Kelvin Espinal, BA⁶, Sarah Russell, BA⁶, 5
- 6 Dennis Camp, BA⁶, Charles Connelly, BS⁶, Daniel A. Green, MD^{1, #}
- 8 ¹Department of Pathology & Cell Biology, Columbia University Irving Medical Center, New York, NY
- 9 ²Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY
- 10 ³Division of Infectious Diseases, Department of Internal Medicine, Weill Cornell Medicine, New York,
- 11 NY

16

19

1

2

7

- 12 ⁴Division of Infectious Diseases, Department of Internal Medicine, Columbia University Irving Medical
- 13 Center, New York, NY
- 14 ⁵Department of Pathology and Clinical Laboratories, NewYork-Presbyterian Queens Hospital
- 15 ⁶Clinical Laboratories, New York-Presbyterian Hospital, New York, NY
- 17 Keywords: COVID-19, SARS-CoV-2, Bacteremia, Sepsis, Blood Culture
- 18 Running Title: Blood Culture COVID-19
- 20 #Address correspondence to:
- 21 Daniel A. Green, M.D.
- 22 3959 Broadway
- 23 Microbiology, CHONY C-324
- 24 New York, NY 10032
- 25 (212)-305-6301
- 26 dag2149@cumc.columbia.edu

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

Abstract: A surge of patients with coronavirus disease 2019 (COVID-19) presenting to New York City hospitals in March 2020 led to a sharp increase in the utilization of blood cultures, which overwhelmed the capacity of automated blood culture instruments. We sought to evaluate the utilization and diagnostic yield of blood cultures during the COVID-19 pandemic to determine prevalence and common etiologies of bacteremia, and to inform a diagnostic approach to relieve blood culture overutilization. We performed a retrospective cohort analysis of 88,201 blood cultures from 28,011 patients at a multicenter network of hospitals within New York City to evaluate order volume, positivity rate, time to positivity, and etiologies of positive cultures in COVID-19. Ordering volume increased by 34.8% in the second half of March 2020 compared to the first half of the month. The rate of bacteremia was significantly lower among COVID-19 patients (3.8%) than COVID-19 negative patients (8.0%) and those not tested (7.1%), p < 0.001. COVID-19 patients had a high proportion of organisms reflective of commensal skin microbiota, reducing the bacteremia rate to 1.6% when excluded. More than 98% of all positive cultures were detected within 4 days of incubation. Bloodstream infections are very rare for COVID-19 patients, which supports the judicious use of blood cultures in the absence of compelling evidence for bacterial coinfection. Clear communication with ordering providers is necessary to prevent overutilization of blood cultures during COVID-19 surges, and laboratories should consider shortening the incubation period from 5 days to 4 days to free additional capacity.

Introduction:

The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) across New York City in March 2020 led to an unprecedented strain on hospital resources, including shortages of beds, ventilators, personal protective equipment, and diagnostic materials such as laboratory reagents and nasopharyngeal swabs ¹⁻³. The surge of febrile patients to our network of hospitals in New York City led to a sudden and dramatic increase in the number of blood cultures received in our laboratories, which overwhelmed the capacity of our automated blood culture instruments.

While blood cultures are an essential tool for the diagnosis and management of bloodstream infections among patients presenting to the emergency department and among inpatients, data are lacking on their utility for patients with suspected or confirmed coronavirus disease 19 (COVID-19). While many patients with severe COVID-19 are treated with empiric antibiotics for potential bacterial co-infections, the rate of bacteremia among these patients is unknown, and the benefit of empiric antibiotic therapy is unproven. Frequent ordering of blood cultures for patients with COVID-19 may overwhelm a laboratory's capacity to perform and result these tests, which may negatively impact the overall benefit of testing for the entire medical center. Therefore, we sought to evaluate both the utilization and diagnostic yield of blood cultures during a surge of COVID-19 patients presenting to our hospitals, including positivity rates for patients with and without COVID-19, as well as the most common causes of bacteremia among COVID-19 patients. We also relay strategies for diagnostic stewardship to mitigate challenges that may arise from a surge of blood culture orders.

Methods:

Study Design:

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

A retrospective cohort study was conducted on patients with blood cultures performed at New York-Presbyterian Hospitals located throughout New York City from January 1, 2020 to March 31, 2020. Corresponding data from January 1, 2019 to March 31, 2019 were collected to establish a seasonal historic baseline of blood culture ordering and positivity. Records were extracted from the laboratory information system (Cerner Millennium, Cerner, North Kansas City, MO) using a Cerner Command Language query and included information on performing facility, SARS-CoV-2 reverse transcriptionpolymerase chain reaction (RT-PCR) result, blood culture result, organism(s) identified, and blood culture collection date and time. After the study period concluded, the blood culture incubation period was reduced from 5 days to 4 days to free additional space on the instruments. In a subset of patients for whom data were available, the interval from time of blood culture collection to time of Gram stain was used to calculate the time to blood culture positivity during the study period, which was used to examine the predicted effect of this intervention. Laboratory Methods: Blood cultures were incubated on BACTEC FX (Becton, Dickinson and Co., Franklin Lakes, NJ) or VersaTrek (Thermo Fisher Scientific, Inc., Waltham, MA) instruments for a maximum of 5 days. SARS-CoV-2 RT-PCR testing was performed in-house with the following assays: cobas SARS-CoV-2 (Roche Molecular Systems, Inc., Branchburg, NJ), Xpert Xpress SARS-CoV-2 (Cepheid, Sunnyvale, CA), RealStar SARS-CoV-2 (Altona Diagnostics USA, Inc., Plain City, OH), and a laboratory-developed test developed by the Wadsworth Center at the New York State Department of Health. Participants: A total of 88,201 blood cultures from 28,011 patients were included from the following hospitals within the NewYork-Presbyterian network: Columbia University Irving Medical Center (32,788), Weill-

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

Cornell Medical Center (26,794), Allen Hospital (6,053), Queens Hospital (16,913), and Lower Manhattan Hospital (5,653). Patients were stratified by SARS-CoV-2 RT-PCR result as positive, negative, or not tested. For the purposes of classifying blood cultures by SARS-CoV-2 RT-PCR status, we used the following criteria: 1. Blood cultures were labeled as SARS-CoV-2 status "Positive" if the blood culture was performed within 2 days of a positive SARS-CoV-2 RT-PCR result and for all subsequent blood cultures after a positive SARS-CoV-2 RT-PCR result. 2. Blood cultures were labeled as SARS-CoV-2 status "Negative" if the blood culture was performed within 2 days of a negative SARS-CoV-2 RT-PCR result and for all subsequent blood cultures, unless the patient had a subsequent positive SARS-CoV-2 RT-PCR result, for which the status was changed to "Positive" for any blood cultures performed within 2 days of the positive SARS-CoV-2 RT-PCR result. 3. All other blood cultures were labeled as SARS-CoV-2 status "Not tested." The 2-day interval was used to account for turnaround time from test ordering to SARS-CoV-2 test results, as blood culture and SARS-CoV-2 RT-PCR tests ordered on the same day may have taken up to 2 days for the SARS-CoV-2 RT-PCR result to become available. This study was approved by the Institutional Review Boards of Columbia University Irving Medical Center and Weill-Cornell Medicine. Data Analysis: All data analysis was performed with the R statistical language version 3.6.3 (R Core Team (2020). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org). Blood culture volumes and positivity rates were calculated and graphed by day, with a moving regression line estimated by the default geom_smooth function of the ggplot2 R package version 3.3.0, namely locally estimated scatterplot smoothing (LOESS) for data with less than 1000 points and generalized additive model (GAM) for data with more than 1000 points. The regression lines were overlayed in the scatterplot to analyze directional trends.

Volumes and positivity rates were also stratified by SARS-CoV-2 RT-PCR result using the rules specified above, and by various patient categories. Bacterial and fungal etiologies of blood cultures were also collected and stratified by SARS-CoV-2 RT-PCR result. Differences in continuous data between groups were assessed by one-way analysis of variation (ANOVA), whereas categorical data were analyzed by Pearson's chi-squared analysis. Categorical data were graphed by the *assoc* function of the *vcd* R package (version 1.4.7) and colored according to Pearson's residuals to demonstrate sources of difference between observed and expected proportions in different groups.

Results:

further (Figure 2).

Blood Culture Volumes and Positivity Rate:

During the study period, blood culture volumes rose substantially during the month of March 2020 (**Figure 1**). Overall, 8,784 blood cultures were performed during the second half of March 2020, representing a 34.8% increase from the first half of the month. Patients who were positive for SARS-CoV-2 accounted for the majority of the increased blood culture ordering. Notably, the increased ordering among COVID-19 patients was not primarily attributable to repeated ordering, as 48.2% of COVID-19 patients had more than 2 blood culture sets drawn, compared to 66.2% of COVID-19 negative patients and 62.1% of patients not tested for SARS-CoV-2 (p <0.001, **Supplemental Tables 1 and 2**)

The blood culture positivity rate was significantly lower for patients that tested positive for SARS-CoV-2 (3.8%) than for patients that tested negative for SARS-CoV-2 (8.0%) or for patients that were not tested (7.1%, p < 0.001, **Table 1**). As additional COVID-19 patients presented to the hospital throughout the month of March 2020, the overall rate of blood culture positivity continued to decrease

Etiologies of Bacteremia:

Among patients with positive blood cultures, COVID-19 patients had a significantly higher proportion of cultures that likely represented contamination with normal skin microbiota than all other groups (**Figure 3 and Table 2**). Organisms were labeled as likely contaminants if they were isolated only once per patient and belonged to groups generally defined as commensal skin microbiota. Coagulase-negative *Staphylococcus* species accounted for 59.7% of all positive cultures among COVID-19 patients, compared to 32.0% among patients that tested negative for SARS-CoV-2, and 29.8% among patients that were not tested for SARS-CoV-2 in 2020 (p < 0.001). *Corynebacterium* species, *Bacillus* species, and *Micrococcus* species were also seen more frequently among COVID-19 patients (**Supplemental Table 3**). When potential contaminants were excluded, the rate of bacteremia for COVID-19 patients decreased to 1.6%, which was significantly lower than the rate of bacteremia excluding contaminants among COVID-19 negative patients (5.9%) and during the same period in 2019 (5.7%, p < 0.001, **Table 3**). The most common causes of true bacteremia among COVID-19 patients were *Escherichia coli* (16.7%), *Staphylococcus aureus* (13.3%), *Klebsiella pneumoniae* (10.0%), and *Enterobacter cloacae* complex (8.3%) (**Supplemental Table 3**). None of these pathogens were overrepresented among COVID-19 patients compared to the other groups.

Incubation Period:

Among the subset of 1859 positive blood cultures for which incubation period could be reliably assessed, the vast majority (88.2%) signaled positive within 1-2 days of incubation, with an additional 7.0% signaling positive on day 3 and 3.0% signaling positive on day 4 (**Figure 4 and Supplemental Table 4**). Only 1.8% of all blood cultures signaled positive on day 5, many of which yielded normal skin microbiota (**Supplemental Table 5**). Among COVID-19 patients, 97.3% of positive cultures signaled

positive within 3 days of incubation, with one culture positive on the 4th day for *Cutibacterium acnes* and one culture positive on the 5th day for *Candida albicans*.

Discussion:

Beginning in March 2020, a surge of COVID-19 patients presenting to our network of hospitals in New York City, the current epicenter of the global COVID-19 pandemic⁵, led to a dramatic increase in the utilization of blood cultures. In patients presenting with severe febrile illness, blood cultures are essential in ruling out bacterial infection and guiding appropriate antibiotic utilization. However, we found a very low rate of bacteremia among patients diagnosed with COVID-19, implying a remarkably low diagnostic yield of blood cultures for COVID-19 patients. When excluding likely contaminants, COVID-19 patients had bacteremia rates that were less than one third of the baseline rate from 2019. These data demonstrate that bloodstream infections appear to be very rare for COVID-19 patients, and suggest that empiric antibiotics may not be useful in the absence of compelling evidence of an accompanying bacterial infection. Notably, we did not evaluate other bacterial infections such as bacterial pneumonia, although other studies have shown low levels of procalcitonin among COVID-19 patients, arguing that bacterial superinfection may be uncommon ⁶⁻⁸.

As medical centers across the United States prepare for anticipated waves of COVID-19 patients, our data may be used to justify the judicious utilization of blood cultures to preserve the operational capacity of diagnostic laboratories and to promote antimicrobial stewardship efforts to reduce unnecessary antibiotic administration. Overordering of blood cultures during a COVID-19 surge within our hospital network resulted in culture volumes that exceeded the capacity of our automated instruments, requiring additional staff to manually process these cultures at a time when staffing and supplies were already constrained. Our experience should serve as a caution to other medical centers that overordering of blood cultures during patient surges can overwhelm laboratory capacity and may negatively impact the quality of results for all patients.

As a harm-reduction measure, we decreased the incubation period of blood cultures from 5 days to 4 days after the study period concluded, which freed additional space to allow for timely processing of incoming cultures. Our data demonstrate that this intervention likely had little to no adverse effect on patient care, as all but one COVID-19 patients with positive cultures during the study period signaled positive within 4 days, and only 1.8% of all positive cultures signaled positive on the 5th day, many of which were positive for normal skin microbiota. Previous studies have also shown that decreasing the incubation of blood cultures to 4 days ⁹ or even 3 days ^{10,11} has minimal effect on positivity rates, particularly for clinically significant bacteria.

To our knowledge, this study is the first to examine blood culture utilization among COVID-19 patients. The inclusion of over 88,000 patient cultures is a major strength of the study design, as is the multicenter analysis from a wide geographic catchment area in New York City, which increases the generalizability of our results. Limitations of the study include paucity of data on other bacterial co-

In summary, we observed an overutilization of blood cultures during a surge of COVID-19 patients to our network of medical centers in New York City and found a very low rate of bloodstream infections among COVID-19 patients. This overutilization was mitigated through a 4 day incubation with likely minimal impact on patient care. Clear communication with ordering providers and hospital leadership regarding the low yield of blood cultures is a necessary step to mitigate overordering and to preserve laboratory functionality during these periods. Laboratories should also consider reducing the incubation period of blood cultures from 5 days to 4 days to further increase their capacity.

infections and lack of data on patient antibiotic utilization to demonstrate how blood culture utilization

Acknowledgments:

impacted therapy.

Potential conflicts of interest: J.J.C. has received research support from Roche Diagnostics. All other authors have no conflicts.

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

References: Fomsgaard AS, Rosenstierne MW. An alternative workflow for molecular detection of 1. SARS-CoV-2 - escape from the NA extraction kit-shortage, Copenhagen, Denmark, March 2020. Euro Surveill. 2020;25(14). 2. Newton PN, Bond KC, signatories from c. COVID-19 and risks to the supply and quality of tests, drugs, and vaccines. Lancet Glob Health. 2020. 3. Ranney ML, Griffeth V, Jha AK. Critical Supply Shortages - The Need for Ventilators and Personal Protective Equipment during the Covid-19 Pandemic. N Engl J Med. 2020. 4. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health careassociated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36(5):309-332. 5. New York City Department of Health COVID-19 Data. https://www1.nyc.gov/site/doh/covid/covid-19-data.page. Accessed April 21, 2020. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. 6. N Engl J Med. 2020. 7. Lippi G, Plebani M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. Clin Chim Acta. 2020;505:190-191. 8. Lippi G, Plebani M. Laboratory abnormalities in patients with COVID-2019 infection. Clin Chem Lab Med. 2020.

9. Doern GV, Brueggemann AB, Dunne WM, Jenkins SG, Halstead DC, McLaughlin JC. Fourday incubation period for blood culture bottles processed with the Difco ESP blood culture system. J Clin Microbiol. 1997;35(5):1290-1292. Bourbeau PP, Foltzer M. Routine incubation of BacT/ALERT FA and FN blood culture 10. bottles for more than 3 days may not be necessary. J Clin Microbiol. 2005;43(5):2506-2509. 11. Bourbeau PP, Pohlman JK. Three days of incubation may be sufficient for routine blood cultures with BacT/Alert FAN blood culture bottles. J Clin Microbiol. 2001;39(6):2079-2082.

<u>Tables</u>

278

279

280

282 283

Table 1A - Distribution of blood culture results by SARS-CoV-2 status

			•				
SARS-CoV-2	Jan-Feb,	Mar 1-15,	Mar 16-31,	Jan-Feb,	Mar 1-15,	Mar 16-31,	
Status	2019	2019	2019	2020	2020	2020	Total
Blood Culture							(N=88203)
Result	(N=29019)	(N=/601)	(N=7688)	(N=28593)	(M=02T8)	(N=8784)	
Not tested							
Negative	27022	7074	7065	26520	5556	1779	75016
	(93.1%)	(93.1%)	(91.9%)	(92.7%)	(93.5%)	(93.8%)	(92.9%)
Positive	1997	527	623	2073	386	117	5723
	(6.9%)	(6.9%)	(8.1%)	(7.3%)	(6.5%)	(6.2%)	(7.1%)
Negative							
Negative	0	0	0	0	431	2317	2748
	U	U	U	U	(93.7%)	(91.7%)	(92.0%)
Positive	0	0	0	0	20 (6 20/)	209	238
	U	0 0 2		29 (6.3%)	(8.3%)	(8.0%)	
Positive							
Negative	0	0	0	0	110	4198	4308
	0	0	0	0	(94.8%)	(96.2%)	(96.2%)
Positive	0	0	0	0	C /E 20/\	164	170
	0	U	0	0	6 (5.2%)	(3.8%)	(3.8%)

Table 1B - Distribution of blood culture results collected in March 2020 by SARS-CoV-2 status.

Blood Culture Date		Not tested (N=7838)	Negative (N=2986)	Positive (N=4478)	Total (N=15302)	p value
Mar 1-15, 2020	Blood Culture Result	!				0.840 ¹
	Negative	5556 (93.5%)	431 (93.7%)	110 (94.8%)	6097 (93.5%)	
	Positive	386 (6.5%)	29 (6.3%)	6 (5.2%)	421 (6.5%)	
Mar 16-31, 2020	Blood Culture Result					<0.001 ¹
	Negative	1779 (93.8%)	2317 (91.7%)	4198 (96.2%)	8294 (94.4%)	
	Positive	117 (6.2%)	209 (8.3%)	164 (3.8%)	490 (5.6%)	

1. Pearson's Chi-squared test

Table 2 - Most frequent microorganism groups isolated from blood cultures by SARS-CoV-2 status. Each species was counted once per patient, independently of how often it was isolated from each patient, then grouped by the conventional categories.

	Not tested	Negative	Positive	Total	
	(N=3928)	(N=153)	(N=159)	(N=4240)	p value
Microorganism					<0.001 ¹
Staphylococcus aureus	344 (8.8%)	15 (9.8%)	8 (5.0%)	367 (8.7%)	
Coagulase-negative Staphylococcus	1169 (29.8%)	49 (32.0%)	95 (59.7%)	1313 (31.0%)	
Other Gram-positive cocci	702 (17.9%)	25 (16.3%)	21 (13.2%)	748 (17.6%)	
Gram-negative rods	1187 (30.2%)	42 (27.5%)	16 (10.1%)	1245 (29.4%)	
Gram-positive rods	236 (6.0%)	5 (3.3%)	15 (9.4%)	256 (6.0%)	
Gram-negative cocci	6 (0.2%)	0 (0.0%)	0 (0.0%)	6 (0.1%)	
Anaerobes	171 (4.4%)	10 (6.5%)	2 (1.3%)	183 (4.3%)	
Yeast	113 (2.9%)	7 (4.6%)	2 (1.3%)	122 (2.9%)	

^{1.} Pearson's Chi-squared test

Table 3 - Distribution of blood culture results by date and SARS-CoV-2 Status. Organisms were labeled as likely contaminants if they were isolated only once per patient and belong to the groups generally defined as skin contaminants

Blood Culture Date		Not tested (N=80739)	Negative (N=2986)	Positive (N=4478)	Total (N=88203)	p value	
Jan-Feb	BC Result						
2019	Negative	27022 (93.1%)	0	0	27022 (93.1%))	
	Likely Contaminant	636 (2.2%)	0	0	636 (2.2%)		
	Positive	1361 (4.7%)	0	0	1361 (4.7%)		
Mar	BC Result						
1-15,	Negative	7074 (93.1%)	0	0	7074 (93.1%)		
2019	Likely Contaminant	154 (2.0%)	0	0	154 (2.0%)		
	Positive	373 (4.9%)	0	0	373 (4.9%)		
Mar	BC Result						
16-31, 2019	Negative	7065 (91.9%)	0	0	7065 (91.9%)		
	Likely Contaminant	186 (2.4%)	0	0	186 (2.4%)		
	Positive	437 (5.7%)	0	0	437 (5.7%)		
Jan-Feb	BC Result						
2020	Negative	265 20 (92.7%)	0	0	26520 (92.7%)		
	Likely Contaminant	624 (2.2%)	0	0	624 (2.2%)		
	Positive	1449 (5.1%)	0	0	1449 (5.1%)		
Mar 1-15, 2020	BC Result					0.431^{1}	
	Negative	5556 (93.5%)	431 (93.7%)	110 (94.8%)	6097 (93.5%)		
	Likely Contaminant	128 (2.2%)	7 (1.5%)	4 (3.4%)	139 (2.1%)		
	Positive	258 (4.3%)	22 (4.8%)	2 (1.7%)	282 (4.3%)		
Mar 16-31, 2020	BC Result					<0.001	
	Negative	1779 (93.8%)	2317 (91.7%)	4198 (96.2%)	8294 (94.4%)		
	Likely Contaminant	31 (1.6%)	59 (2.3%)	96 (2.2%)	186 (2.1%)		
	Positive	86 (4.5%)	150 (5.9%)	68 (1.6%)	304 (3.5%)		

^{1.} Pearson's Chi-squared test

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

Figure Legends: Figure 1: Blood culture ordering volume by day in 2019 and 2020. Total blood cultures are shown in purple and are broken down by SARS-CoV-2 status of "Positive" in blue, "Negative" in red, and "Not tested" in green. Figure 2: Rate of blood culture positivity by day in 2019 and 2020. The percentage of positive blood cultures is shown in red and the total number of negative blood cultures is shown in blue. Figure 3: Frequency of microorganisms identified from positive blood cultures stratified by SARS-CoV-2 status. Each microorganism was counted once per patient and grouped by the categories specified in the figure legends. A. All microorganisms isolated were counted. B. Likely skin contaminant were excluded. *** Pearson's chi-square p-value < 0.001. Figure 4: Time to positivity of positive blood cultures stratified by SARS-CoV-2 status. Time to positivity was calculated from the time of collection to the first positive signal as recorded by the gram stain date/time. The scaled density distribution of the time to positivity is shown as color-filled density plots and the cumulative distribution of positivity over time is represented by solid lines.

Figure 1 - Blood Culture Volumes 600 -400 -2019 200 -SARS-CoV-2 Status Count of Tests 0 -Negative Not tested 600 -Positive Total 400 -2020 200 -

01-Mar

01-Apr

0 -

01-Jan

01-Feb

Date Ordered

Figure 2 - % Positive Blood Cultures (in red) and Number of Negative Blood Cultures (in blue)




Figure 3-A. All positive cultures per patient




Figure 3-B. Positive cultures per patient after excluding likely contaminants

